Patent intelligence · US
US 6110461
Reovirus for the treatment of neoplasia
Reovirus for the treatment of neoplasia
Patent details — US 6110461
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 29, 2000
- Expiration
- Aug 24, 2020
- Applicant
- ONCOLYTICS BIOTECH INC.
- Claims
- 39
- CPC classes
- A61K, A61K35/765, A61P, A61P35/00
Quick answer
US 6110461 (Reovirus for the treatment of neoplasia) is held by ONCOLYTICS BIOTECH INC.. Status: expired. Granted Aug 29, 2000. Expires Aug 24, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ONCOLYTICS BIOTECH INC.
- Grant date
- Expiration
- Claims
- 39
- CPC classes
- A61K, A61K35/765, A61P, A61P35/00, A61P35/02, A61P35/04
More from ONCOLYTICS BIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 11542526
Oncolytic adenoviral vector and methods of use
granted -
US 11246930
Reoviruses having modified sequences
granted -
US 10596260
Reoviruses having modified sequences
granted -
US 10167452
Viral purification methods
granted -
US 10039827
Reoviruses having modified sequences
granted -
US 9610352
Lyophilized viral formulations
granted -
US 9610309
Liquid viral formulations
granted -
US 9365823
Virus clearance of neoplastic cells from mixed cellular compositions
granted
Frequently asked questions
What is US patent 6110461?
US 6110461 (Reovirus for the treatment of neoplasia) is held by ONCOLYTICS BIOTECH INC.. Status: expired. Granted Aug 29, 2000. Expires Aug 24, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6110461?
ONCOLYTICS BIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 66 pharmaceutical patents for this assignee.
When does US 6110461 expire?
Our index shows an expiration date of Aug 24, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.